Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293137 · ClinicalTrials.gov registry record
NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy
A clinical trial, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- 60
- Enrollment target
NCT00293137 is a clinical trial that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 60 participants.
The verdict
NCT00293137 was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with chronic systolic heart (Dilated cardiomyopathy). We hypothesize that in patients with heart failure, rosiglitazone is safe, and can reduce nitric oxide (NO) derived oxidative stress (in particular, nitrotyrosine) thereby improving endothelial dysfunction, left ventricular performance, and metabolic parameters.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293137
The ClinicalTrials.gov registry entry for NCT00293137 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00293137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293137 about?
NCT00293137 is a clinical study titled "NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy". The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with chronic systolic heart (Dilated cardiomyopathy). We hypothesize that in patients with heart failure, rosiglitazone is safe, and can reduce nitric oxide (NO) derived oxidative stress (in particular, nitrotyr...
What is the current status of trial NCT00293137?
This trial is currently terminated. The enrollment target is 60 participants. The study started on 2006-02. Estimated completion is 2007-08.
Who is sponsoring clinical trial NCT00293137?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.